Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Tarsus Pharmaceuticals (TARS) Equity Ratio (2020 - 2025)

Historic Equity Ratio for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Q3 2025 value amounting to 0.63.

  • Tarsus Pharmaceuticals' Equity Ratio fell 67.61% to 0.63 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.63, marking a year-over-year decrease of 67.61%. This contributed to the annual value of 0.6 for FY2024, which is 1972.85% down from last year.
  • Per Tarsus Pharmaceuticals' latest filing, its Equity Ratio stood at 0.63 for Q3 2025, which was down 67.61% from 0.67 recorded in Q2 2025.
  • Tarsus Pharmaceuticals' Equity Ratio's 5-year high stood at 0.95 during Q2 2021, with a 5-year trough of 0.6 in Q4 2024.
  • For the 5-year period, Tarsus Pharmaceuticals' Equity Ratio averaged around 0.79, with its median value being 0.8 (2023).
  • Its Equity Ratio has fluctuated over the past 5 years, first skyrocketed by 58644.8% in 2021, then plummeted by 2074.23% in 2024.
  • Quarter analysis of 5 years shows Tarsus Pharmaceuticals' Equity Ratio stood at 0.93 in 2021, then fell by 9.16% to 0.85 in 2022, then fell by 12.35% to 0.74 in 2023, then fell by 19.73% to 0.6 in 2024, then grew by 5.25% to 0.63 in 2025.
  • Its Equity Ratio stands at 0.63 for Q3 2025, versus 0.67 for Q2 2025 and 0.68 for Q1 2025.